Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18396806 | 0.93 | MGLL (0.47) | MGLLPOLBTP53MAPTNPC1 | |
| SCHEMBL7037968 | 0.91 | MGLL (0.41) | MGLLPOLBTP53MAPTNPC1 | |
| SCHEMBL8306382 | 0.87 | MAPT (0.50) | MGLLPOLBTP53MAPTNPC1 | |
| SCHEMBL18787217 | 0.86 | PRKDC (0.57) | MGLLPOLBTP53MAPTNPC1 | |
| SCHEMBL6517565 | 0.86 | NPC1 (0.44) | MGLLPOLBTP53MAPTNPC1 | |
| SCHEMBL30762759 | 0.85 | MGLL (0.47) | MGLLPOLBTP53MAPTNPC1 | |
| SCHEMBL14872041 | 0.84 | MGLL (0.47) | MGLLPOLBTP53MAPTNPC1 | |
| SCHEMBL18787363 | 0.84 | MGLL (0.47) | MGLLPOLBTP53MAPTNPC1 | |
| SCHEMBL5283837 | 0.84 | MGLL (0.50) | MGLLPOLBTP53MAPTNPC1 | |
| SCHEMBL18396765 | 0.83 | MAPT (0.47) | MGLLTP53MAPTNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062394-A1 | PROCESSES FOR PREPARING OXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4121058-B1 | OXAZOLIDINONE COMPOUND AND ITS USE THEREOF AS AN ANTIBACTERIAL AGENT | MERCK SHARP & DOHME LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12435077-B2 | Oxazolidinone compound and methods of use thereof as an antibacterial agent | MERCK SHARP & DOHME LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20240208958-A1 | OXAZOLIDINONE COMPOUND AND METHODS OF USE THEREOF AS AN ANTIBACTERIAL AGENT | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208958-A1 | OXAZOLIDINONE COMPOUND AND METHODS OF USE THEREOF AS AN ANTIBACTERIAL AGENT | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4121058-A1 | OXAZOLIDINONE COMPOUND AND METHODS OF USE THEREOF AS AN ANTIBACTERIAL AGENT | Merck Sharp & Dohme LLC (US) | 2023-01-25 | — | — | EP | disclosed |
| US-7473699-B2 | 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2009-01-06 | — | — | US | disclosed |
| EP-1328509-B1 | METHODS OF PRODUCING OXAZOLIDINONE COMPOUNDS | PHARMACIA & UPJOHN CO LLC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-6998420-B2 | Oxazolidinone compounds | PHARMACIA & UPJOHN COMPANY (US) | 2006-02-14 | — | — | US | disclosed |
| EP-1294717-B1 | A THIAZINE OXAZOLIDINONE | PHARMACIA & UPJOHN CO LLC (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6833453-B2 | As an example, manufacturing a 5-(tert-butylcarbamoyl)-amino-methyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or a 3-amino-1-halopropanol | PHARMACIA & UPJOHN COMPANY | 2004-12-21 | — | — | US | disclosed |
| US-20040143131-A1 | in particular,manufacturing a 5-(tert-butylcarbamoyl)-aminomethyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or 3-amino-1-halopropanol, intermediates | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2003072575-A1 | 3-CYCLYL-5-(NITROGEN-CONTAINING 5-MEMBERED RING) METHYL-OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2003-09-04 | — | — | WO | disclosed |
| US-6605609-B2 | N-(((5S)-3-(4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophen yl) -2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide antimicrobial used in combination therapy | PHARMACIA & UPJOHN COMPANY | 2003-08-12 | — | — | US | disclosed |
| EP-1328509-A1 | METHODS OF PRODUCING OXAZOLIDINONE COMPOUNDS | Pharmacia & Upjohn Company (US) | 2003-07-23 | — | — | EP | disclosed |
| EP-1294717-A2 | A THIAZINE OXAZOLIDINONE | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020156072-A1 | Thiazine oxazolidinone | PHARMACIA & UPJOHN COMPANY | 2002-10-24 | — | — | US | disclosed |
| US-20020086900-A1 | Methods of producing oxazolidinone compounds | PERRAULT WILLIAM R (US) | 2002-07-04 | — | — | US | disclosed |
| WO-2002032857-A1 | METHODS OF PRODUCING OXAZOLIDINONE COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
| WO-2001098297-A2 | A THIAZINE OXAZOLIDINONE | PHARMACIA & UP JOHN COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156072-A1 | Thiazine oxazolidinone | OXA1L, TLR5, TALDO1 | MGLL 1436/4885POLB 2375/4885TP53 4472/4885 |
| US-12435077-B2 | Oxazolidinone compound and methods of use thereof as an antibacterial agent | OXA1L, IL17A, TBCD | MGLL 2511/4885POLB 1828/4885TP53 4373/4885 |
| US-20040143131-A1 | in particular,manufacturing a 5-(tert-butylcarbamoyl)-aminomethyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or 3-amino-1-halopropanol, intermediates | TET1, NAT10, TET3 | MGLL 1782/4885POLB 132/4885TP53 3260/4885 |
| US-20260062394-A1 | PROCESSES FOR PREPARING OXAZOLIDINONE COMPOUNDS | KDM5D, TBCD, TBC1D5 | MGLL 1924/4885POLB 3069/4885TP53 4711/4885 |
| US-20240208958-A1 | OXAZOLIDINONE COMPOUND AND METHODS OF USE THEREOF AS AN ANTIBACTERIAL AGENT | OXA1L, IL17A, TBCD | MGLL 2511/4885POLB 1828/4885TP53 4373/4885 |
| US-20020086900-A1 | Methods of producing oxazolidinone compounds | TET3, TET1, AZI2 | MGLL 2455/4885POLB 172/4885TP53 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.